{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:26:25Z","timestamp":1785338785078,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2003<\/jats:bold>\n                    Desmoglein (Dsg) enzyme\u2010linked immunosorbent assay (ELISA) is a highly sensitive and specific method to detect anti\u2010Dsg3 and anti\u2010Dsg1 IgG autoantibodies in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), respectively. Whereas ELISA index values fluctuate in parallel with disease activity, ELISA positivity during clinical remission has been observed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2003<\/jats:bold>\n                    To determine the prevalence of positive Dsg ELISA index values during clinical remission. To ascertain how positive Dsg ELISA scores during remission compare with those during active disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2003<\/jats:bold>\n                    Dsg ELISA was performed on serum samples of PV and PF patients taken during remission (lesion\u2010free \u2265\u00a03\u00a0months on \u2264\u00a015\u00a0mg or \u2264\u00a05\u00a0mg\/day prednisolone) and active disease. We used a modified ELISA protocol with optimal serum dilutions in sera with very high initial index values, as we previously described.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2003<\/jats:bold>\n                    When remission was defined as no eruption \u2265\u00a03\u00a0months with \u2264\u00a015\u00a0mg\/day prednisolone, 20 of 43\u00a0PV patients (46.5%) and 4 of 12 PF patients (33.3%) showed Dsg3 and Dsg1 ELISA positivity, respectively. With \u2264\u00a05\u00a0mg\/day, 6 of 17\u00a0PV (35.3%) and 1 of 6 PF patients (16.7%) showed Dsg3 and Dsg1 ELISA positivity, respectively. The index value of each ELISA\u2010positive remission serum was consistently lower than that of its corresponding active disease serum. We observed consistent correlation between ELISA index values and indirect immunofluorescence titres.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2003<\/jats:bold>\n                    Circulating anti\u2010Dsg IgG autoantibodies are found in a considerable percentage of pemphigus patients in remission, who have high levels of antibody production during active stages.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2008.02715.x","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T13:44:21Z","timestamp":1207835061000},"page":"1070-1075","source":"Crossref","is-referenced-by-count":68,"title":["Anti\u2010desmoglein IgG autoantibodies in patients with pemphigus in remission"],"prefix":"10.1111","volume":"22","author":[{"given":"EJ","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90360-B"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60503-9"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70183-0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen\u2010specific enzyme linked immunosorbent assays with baculovirus\u2010expressed recombinant desmogleins","volume":"159","author":"Ishii K","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02752.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90253-6"},{"key":"e_1_2_5_8_2","first-page":"18","article-title":"An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus","volume":"10","author":"Aoyama Y","year":"2000","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2000.tb02187.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04132.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04838.x"},{"key":"e_1_2_5_12_2","first-page":"48","article-title":"Serum levels of autoantibodies to desmoglein 3 in patients with therapy\u2010resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins","volume":"84","author":"Herzog S","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02593.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.25780"},{"key":"e_1_2_5_15_2","first-page":"CR528","article-title":"Detection of pemphigus autoantibodies by IIF and ELISA tests in patients with pemphigus vulgaris and foliaceous and in health relatives","volume":"9","author":"Torzecka JD","year":"2003","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1979.04010040006002"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12531752"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1981.tb02338.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.2.143"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.2.195"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90213-5"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.02715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.02715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:33:31Z","timestamp":1697312011000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.02715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,18]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1468-3083.2008.02715.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02715.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1147866.604954","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,18]]}}}